


PCT/EP2004/052201

AMENDED CLAIMS

21/07/05

10/568760

CLAIMS (AP200506070210 21 FEB 2006)

1. Amidines of formula (I)

5


and pharmaceutically acceptable salts thereof,

wherein Ar is selected from:

10 3'-benzoylphenyl, 3'-(4-chloro-benzoyl)-phenyl, 3'-(4-methyl-benzoyl)-phenyl, 3'-acetyl-phenyl, 3'-propionyl-phenyl, 3'-isobutanoyl-phenyl, 4'-trifluoromethanesulfonyloxy-phenyl, 4'-benzenesulfonyloxy-phenyl, 4'-trifluoromethanesulfonylamino-phenyl, 4'-benzenesulfonylamino-phenyl, 4'-benzenesulfonylmethyl-phenyl, 4'-acetoxymethyl-phenyl, 4'-propionyloxy-phenyl, 4'-benzoyloxy-phenyl, 4'-acetylamino-phenyl, 4'-propionylamino-phenyl, 4'-benzoylamino-phenyl;

15 R is selected from

- H, C₁-C₅-alkyl, phenyl, C₁-C₅-phenylalkyl, C₁-C₅-cycloalkyl, C₁-C₅-alkenyl, C₁-C₅-alkoxy;
- a residue of formula -(CH₂)_n-NR_aR_b wherein n is an integer from 0 to 5 and each R_a and R_b, which may be the same or different, are C₁-C₆-alkyl, C₁-C₆-alkenyl or, alternatively, R_a and R_b, together with the nitrogen atom to which they are bound, form a heterocycle from 3 to 7 members of formula (II),



(II)


wherein W represents a single bond, O, S, N-Rc, Rc being H, C₁-C₆-alkyl or C₁-C₆-alkylphenyl.R' is H, CH₃, CH₂CH₃;

25 R and R' can alternatively, form a heterocycle from 5 to 7 members of formula (III),

BEST AVAILABLE COPY



2



(III)

wherein X represents a residue -O(CH₂)_n- wherein n is an integer from 1 to 3, or a residue -(CH₂)_n- wherein n is an integer from 2 to 4, or the ethylene residue -CH=CH-.

2. Compounds according to claim 1 selected from:

- 5 (R,S) (2-(4-isobutylphenyl)propionamidine hydrochloride
(+) (2-(4-isobutylphenyl)propionamidine hydrochloride
(-) (2-(4-isobutylphenyl)propionamidine hydrochloride
(R,S) 2-(3-benzoylphenyl)propionamidine hydrochloride
(R,S) 2-[(3-fluoro-4-phenyl)phenyl]propionamidine hydrochloride
10 (R,S) 2-(4-trifluoromethanesulfonyloxyphenyl)propionamidine hydrochloride
(R,S) 2-(5-benzoyl-2-thiophene)propionamidine hydrochloride
(R,S) 2-(4-isobutylphenyl)-N-[3"- (N'-piperidino)propyl]propionamidine dihydrochloride
(R,S) 2-(4-isobutylphenyl)-N-methyl-propionamidine hydrochloride
15 (R,S) 2-(3-benzoylphenyl)- N-[3-(N,N-dimethylamino)propyl]propionamidine hydrochloride
(R,S) 2-(4-isobutylphenyl)propionamidine acetate salt
(R,S) 2-(4-isobutylphenyl)-N-[3-(N,N-dimethylamino)propyl] propionamidine
(R,S) 2-(4-isobutylphenyl)-N-benzyl propionamidine
20 (R,S) 3-[1-(4-isobutylphenyl)ethyl]-5,6-dihydro-2H-1,2,4-oxadiazine
(R,S) 2-[1-(4-isobutylphenyl)ethyl]-4,5-dihydro-2H-1,3,imidazole.


20 3. Compounds according to claims 1 or 2, for use as medicaments.

4. Use of compounds according to claims 1 or 2 in the preparation of a medicament for the treatment of diseases that involve the chemotaxis of human PMNs induced by interleukin-8.
5. Use of compounds according to claims 1 or 2 in the preparation of a medicament for the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
25 6. Pharmaceutical compositions comprising a compound according to claims 1 or 2 in admixture and a suitable carrier thereof.

BEST AVAILABLE COPY

3

7. Use of amidines of formula (I)




(I)

5 and pharmaceutically acceptable salts thereof,
 wherein Ar is a phenyl group non-substituted or substituted by one or more groups
 independently selected from halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, hydroxy, C₁-C₄-acyloxy,
 phenoxy, cyano, nitro, amino, C₁-C₄-acylamino, halogen-C₁-C₃-alkyl, halogen C₁-C₃-alkoxy,
 10 benzoyl or a substituted or unsubstituted 5-6 membered heteroaryl ring selected from
 pyridine, pyrrole, tiofene, furane, indole.

R is selected from

- H, C₁-C₅-alkyl, phenyl, C₁-C₅-phenyalkyl, C₁-C₅-cycloalkyl, C₁-C₅-alkenyl, C₁-C₅-alkoxy;
- a residue of formula -(CH₂)_n-NRaRb wherein n is an integer from 0 to 5 and each Ra and Rb, which may be the same or different, are C₁-C₆-alkyl, C₁-C₆-alkenyl or, alternatively, Ra and Rb, together with the nitrogen atom to which they are bound, form a heterocycle from 3 to 7 members of formula (II),



(II)


20 wherein W represents a single bond, O, S, N-Rc, Rc being H, C₁-C₆-alkyl or C₁-C₆-alkylphenyl.

R' is H, CH₃, CH₂CH₃.

R and R' can alternatively, form a heterocycle from 5 to 7 members of formula (III),

BEST AVAILABLE COPY


4



(III)

wherein X represents a residue $-O(CH_2)_n-$ wherein n is an integer from 1 to 3, or a residue $-(CH_2)_n-$ wherein n is an integer from 2 to 4, or the ethylene residue $-CH=CH-$ in the preparation of a medicament for the treatment of diseases that involve the chemotaxis of human PMNs induced by interleukin-8.

- 5 8. Use of compounds according to claim 7, wherein R is selected from
 - hydrogen
 - a residue of formula $-(CH_2)_n-NRaRb$, wherein n is an integer from 2 to 3 and the group NraRb is selected from N,N-dimethylamine or 1-piperidyl, and R' is H, or R and R' form a
 10 heterocycle of formula (III), where X represents a residue $-O(CH_2)_n-$ wherein n is the integer 1 or 2, or a residue $-(CH_2)_2$.
- 15 9. Use of compounds according to claims 7 or 8 in the preparation of a medicament for the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
- 10 10. Process for the preparation of compounds of formula (I) according to claim 1 comprising the reaction of a nitrile derivate of formula (IV),



(IV)

20 wherein Ar has the same meaning as defined in claim 1, with an amine of formula NHR, wherein R has the same meaning as defined in claim 1.

11. Process for the preparation of compounds of formula (I) according to claim 1, wherein R and R' groups form an heterocycle of formula (III), comprising the reaction of amidines of formula (I) wherein R' is H and R is H or OH, with a reagent of formula L-K-L', in the presence of a base, wherein L and L' are leaving groups, and, when R and R' are both H, K

BEST AVAILABLE COPY

5

represents a residue $-(CH_2)_n-$ wherein n is an integer from 2 to 4; when R is OH and R' is H,
K represents a residue $-(CH_2)_n-$ wherein n is an integer from 1 to 3.

BEST AVAILABLE COPY